top of page

Past Clinical Trials

Sandcat – Enrollment Closed

  • Multicenter, Randomized, Double-masked, Sham controlled study to investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered IVT in Patients with Uveitic Macular Edema.

  • More information can be found here.​​​

​

Formycon – Enrollment Closed

  • An Open-Label, Multi-Center, Single-Arm study to evaluate the ocular safety and usability of FYB203 Pre-filled Syringe (PFS) in patients with Wet AMD, Macular Edema following RVO, Diabetic Macular Edema, or Diabetic Retinopathy. ​​​

​

Parasol – Enrollment Closed

  • A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).​​​​

​

​Quasar – Enrollment Closed

  • Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion.​

  • More information can be found here.​​

​​

Clearside Odyssey – Enrollment Closed

​​

Opthea Coast – Enrollment Closed

  • A multicenter, randomized, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.​

  • More information can be found here.​​

​

Valo Health Spectra – Enrollment Closed

  • A Phase 2 randomized, double-masked, placebo controlled, multicenter study to evaluate the safety and efficacy of OPL-0401 oral pill in patients with non-proliferative diabetic retinopathy (NPDR). ​

  • More information can be found here.

​

Kodiak Sciences Inc GLOW – Enrollment Closed

  • A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW). ​

  • More information can be found here.

​​​

​Sandoz Inc/Hexal AG Mylight – Enrollment Closed

  • A 52 week multicenter randomized, 2 arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 (biosimilar) to Eylea, administered intravitreally in patients with neovascular age related macular degeneration.​

  • More information can be found here.

 

GSK – Enrollment Closed

  • A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2798745 in Participants with Diabetic Macular Edema.

  • More information can be found here.

​

​Gyroscope Therapeutics – Enrollment Closed

  • The objective of this study is to evaluate subjects with geographic atrophy (GA) secondary to dry age related macular degeneration (AMD) by sequencing selected genes associated with AMD. Subjects who meet eligibility criteria will have the option to participapte in on-going or future Gyroscope Therapeutics sponsored studies. 

​

​Allergan Sequoia – Enrollment Closed

  • This is a phase 3 study for patients with treatment naive wet age related macular degeneration. This study is evaluating intravitreal abicipar (DARPin based anti-angiogenic drug), in comparison to intravitreal anti-VEGF ranibizmuab (Lucentis) injections. The estimated enrollment is 900 patients. The study started around June 2015, and will end around May 2019.​

  • More information can be found here.

​

​Yosemite – Enrollment Closed

​

​Tenaya – Enrollment Closed

​

​Clearside Topaz - Enrollment Closed

  • A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion.

​

​Novartis Merlin – Enrollment Closed

  • Study of Safety and Efficacy of Brolucizumab (Beovu) 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections.​

  • More information can be found here.

​

​Ophthotech OPH2003 - Enrollment Closed

  • ​This a phase 2a study for fovea-sparing dry age related macular degeneration with unifocal or multifocal atrophy. It is studying intravitreal injections of a drug called Zimura by way of anti-complement C5 mechanism. This study started in January 2016 and the estimated completion date was in April 2019.

​

​Ophthotech ZIMURA – Enrollment Closed

  • To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD).​

  • More information can be found here.

​

​EyeArt – Enrollment Closed

  • ​EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.

  • More information can be found here.

​

​Chendgu Kanghong Biotechnology - Panda Study – Enrollment Closed

​

​Opthea DME – Enrollment Closed

​

​Senju Pharmaceutical Co MT-0814– Enrollment Closed

 

 

​If you would like to participate in our research program please contact our Research Coordinator, Jacque Smith, at (909) 335-8938 or email: jsmith@vrsurgeons.com.

bottom of page